Literature DB >> 1550446

[Research of factors for glucose intolerance in mucoviscidosis].

J J Robert1, E Grasset, M de Montalembert, D Chevenne, I Deschamps, C Boitard, G Lenoir.   

Abstract

Glucose tolerance has been assessed in cystic fibrosis (CF) children using HbA1C and plasma glucose and insulin determinations during an oral glucose tolerance test (OGTT), along with the determination of HLA-DR and islet-cell (ICA) and anti-insulin (IAA) antibodies. Of 49 patients (25 males, 24 females), aged 2 to 21 years (mean = 10.9 years), 29 had normal glucose tolerance (WHO criteria) during OGTT, 14 had impaired glucose tolerance (IGT) and 6 had an isolated hyperglycemia at 120 min. Fasting plasma glucose and HbA1C were significantly higher in IGT than in normoglycemic patients. However, these two parameters showed poor individual predictive value of disturbance in glucose tolerance. Of 14 patients with abnormal OGTT, 7 were aged below 10 years, with 2 as young as 5 years; 8 patients were females. HLA antigens characteristic of type I diabetes tended to be found less frequently in CF patients than in the general population: 9% were DR3, 7% were DR4 and none was DR3/DR4. There were no HLA differences according to glucose tolerance. ICA and IAA were respectively detected in only one patient. Stimulated plasma insulin was low but did not correlate with glucose tolerance. In conclusion, impaired glucose tolerance is common in cystic fibrosis and can be found early in life. Although insulin secretion is decreased in this population, it does not seem to be the only factor responsible for impaired glucose intolerance. The absence of the genetical and immunological characteristics of type I diabetes confirms that glucose intolerance in cystic fibrosis is due to other pathogenetic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1550446

Source DB:  PubMed          Journal:  Arch Fr Pediatr        ISSN: 0003-9764


  2 in total

1.  Glucose tolerance in patients with cystic fibrosis: five year prospective study.

Authors:  S Lanng; A Hansen; B Thorsteinsson; J Nerup; C Koch
Journal:  BMJ       Date:  1995-09-09

Review 2.  Diabetes in cystic fibrosis.

Authors:  B Yung; M E Hodson
Journal:  J R Soc Med       Date:  1999       Impact factor: 18.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.